TW302355B - - Google Patents
Download PDFInfo
- Publication number
- TW302355B TW302355B TW080107032A TW80107032A TW302355B TW 302355 B TW302355 B TW 302355B TW 080107032 A TW080107032 A TW 080107032A TW 80107032 A TW80107032 A TW 80107032A TW 302355 B TW302355 B TW 302355B
- Authority
- TW
- Taiwan
- Prior art keywords
- phenyl
- patent application
- shows
- page
- ethanol
- Prior art date
Links
- 239000002253 acid Substances 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- -1 4-ethoxycarbonylamino-3-cyano-5-fluoro-phenyl Chemical group 0.000 claims description 99
- 150000001875 compounds Chemical class 0.000 claims description 28
- 238000011049 filling Methods 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000003836 4-phenylbutoxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 208000009079 Bronchial Spasm Diseases 0.000 claims description 2
- 206010006482 Bronchospasm Diseases 0.000 claims description 2
- 230000002079 cooperative effect Effects 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims 2
- 208000014181 Bronchial disease Diseases 0.000 claims 1
- QOTLEKKZVSLEIT-UHFFFAOYSA-N C1(=CC=CC=C1)CC[Cu] Chemical compound C1(=CC=CC=C1)CC[Cu] QOTLEKKZVSLEIT-UHFFFAOYSA-N 0.000 claims 1
- 125000006309 butyl amino group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 claims 1
- 239000004312 hexamethylene tetramine Substances 0.000 claims 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract description 4
- 230000000202 analgesic effect Effects 0.000 abstract description 3
- 239000003623 enhancer Substances 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical class NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 abstract description 3
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 230000001741 anti-phlogistic effect Effects 0.000 abstract 1
- 230000001663 anti-spastic effect Effects 0.000 abstract 1
- 229940124630 bronchodilator Drugs 0.000 abstract 1
- 230000001813 broncholytic effect Effects 0.000 abstract 1
- 239000000812 cholinergic antagonist Substances 0.000 abstract 1
- 230000002366 lipolytic effect Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 239000013543 active substance Substances 0.000 description 40
- 239000007789 gas Substances 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000003925 fat Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 7
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 7
- 229920002261 Corn starch Polymers 0.000 description 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 239000008120 corn starch Substances 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241001494479 Pecora Species 0.000 description 6
- 235000013372 meat Nutrition 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 5
- 240000008042 Zea mays Species 0.000 description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 235000005822 corn Nutrition 0.000 description 5
- 235000013312 flour Nutrition 0.000 description 5
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 4
- 235000019688 fish Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- REOJLIXKJWXUGB-UHFFFAOYSA-N mofebutazone Chemical group O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 4
- 235000013379 molasses Nutrition 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 240000005979 Hordeum vulgare Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- 235000019764 Soybean Meal Nutrition 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000002921 anti-spasmodic effect Effects 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 239000004455 soybean meal Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 240000000111 Saccharum officinarum Species 0.000 description 2
- 235000007201 Saccharum officinarum Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 240000006677 Vicia faba Species 0.000 description 2
- 235000010749 Vicia faba Nutrition 0.000 description 2
- 235000002098 Vicia faba var. major Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical group C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- RWRIWBAIICGTTQ-UHFFFAOYSA-N difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 1
- PRBLRGZSVKMPDX-UHFFFAOYSA-N 1-butyl-4-methoxybenzene Chemical compound CCCCC1=CC=C(OC)C=C1 PRBLRGZSVKMPDX-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 125000004889 1-methylethylamino group Chemical group CC(C)N* 0.000 description 1
- RCSGVJZQZAOBSC-UHFFFAOYSA-N 10-phenyldecan-1-amine Chemical compound NCCCCCCCCCCC1=CC=CC=C1 RCSGVJZQZAOBSC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- YOMBUJAFGMOIGS-UHFFFAOYSA-N 2-fluoro-1-phenylethanone Chemical compound FCC(=O)C1=CC=CC=C1 YOMBUJAFGMOIGS-UHFFFAOYSA-N 0.000 description 1
- ATWSSBASLWBBFT-UHFFFAOYSA-N 2-oxo-2-phenylacetyl fluoride Chemical compound FC(=O)C(=O)C1=CC=CC=C1 ATWSSBASLWBBFT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- ZDHZDWSHLNBTEB-UHFFFAOYSA-N 4-methylamphetamine Chemical compound CC(N)CC1=CC=C(C)C=C1 ZDHZDWSHLNBTEB-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 108091071247 Beta family Proteins 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- VBQYQOHXADFRIA-UHFFFAOYSA-N C1=CC=C(C=C1)C2=CC=C(C=C2)CCCCCCCCCCN Chemical compound C1=CC=C(C=C1)C2=CC=C(C=C2)CCCCCCCCCCN VBQYQOHXADFRIA-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000252229 Carassius auratus Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 244000207543 Euphorbia heterophylla Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 239000001358 L(+)-tartaric acid Substances 0.000 description 1
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000269978 Pleuronectiformes Species 0.000 description 1
- 240000002505 Pogostemon cablin Species 0.000 description 1
- 235000011751 Pogostemon cablin Nutrition 0.000 description 1
- 241000287530 Psittaciformes Species 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000287231 Serinus Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241001223864 Sphyraena barracuda Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019742 Vitamins premix Nutrition 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- GHKJXEICAPOWQS-UHFFFAOYSA-K [Au+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O Chemical compound [Au+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O GHKJXEICAPOWQS-UHFFFAOYSA-K 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- URCJRDMSDWTSGZ-UHFFFAOYSA-N benzaldehyde;sodium Chemical compound [Na].O=CC1=CC=CC=C1 URCJRDMSDWTSGZ-UHFFFAOYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- NXSHODVXBOPCHO-UHFFFAOYSA-N benzene-1,2-dicarboxamide;potassium Chemical compound [K].NC(=O)C1=CC=CC=C1C(N)=O NXSHODVXBOPCHO-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N gamma-phenylbutyric acid Natural products OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001129 phenylbutoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229950006768 phenylethanolamine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Λ 6 13 6 五、發明説明(1 ) 本發明傜關於通式(I,)之苯乙醇胺,
0H
(工 (請先閱讀背面之注意事項再填寫本頁) 其對映體及酸加成鹽,特別是供藥用之與無機或有機酸之 生理上可接受之酸加成鹽,其作為藥物及效能增加劑之用 途及其製法。 此新化合物具有價值之藥理性質:除了止痛,消炎, 消支氣管炎,子宮解症,解脂及抗痙孿之效果外,他們更 具有—表倩的和/和/Si —阻斷效果。他們亦可作為 效能增加劑。
Ri示或共2到5個碩原子之烷氧羰基,且 R 2示下式之基圍 經濟部屮央標準局貝工消費合作社印製 (CH2)m-〇-(CH2)n- -chr5-(ch2 或 本紙張尺度逍用中围國家標準(CNS)甲4規格(210x297公釐) 一 3 - 經濟部+央標準局貝工消贽合作社印製 Λ 6 —. _Β6___ 五、發明説明(2 ) 其中 m示數字2到8 , η示數字1到7 , Ρ示數字1到3 , R3和114,其可相同或不同地示氫,氟,氣或溴原子, 甲基,乙基,羥基,甲氣基或乙氣基或 Ra和R4同示亞甲基二氣基或亞乙基二氧基且 R 5示氫原子或甲基或乙基。 例如,如上所定義之Ri及R2基圍可具如下之意義 可示氫原子,甲氧羰基,乙氧羰基,正丙氧羰基,異 丙氧羰基,正丁氣羰基,1一甲基一正丙氣羰基或2—甲 基一正丙氧羰基且 R2可示2 —苯乙基,3 —苯丙基,4 一苯丁基,2 —苯 基一1一甲基乙基,3—苯基一1一甲基一丙基,4一苯 基一1 一甲基一丁基,2 —苯基一1 一乙基一乙基,3 — 苯基一 1 一乙基苯基,4 —苯基—1 一乙基一丁基,2 — (4 一甲氧苯基)_乙基,3— (4 一甲氧苯基)一丙基 ,4 一 (4 一甲氧苯基)丁基,2 — (4 —甲氧苯基)_ 1—甲基一乙基,3_ (4_甲氧苯基)一1 一甲基一丙 基,4 — (4 —甲氧苯基)_1 一甲基一丁基,2 — (4 一甲氧苯基)一 1_乙基一乙基,3_ (4_甲氧苯基) —1—乙基一丙基,4一 (4一甲氧苯基)一1一乙基一 丁基,2 — (4—氯苯基)—乙基,3_ (4 —氯苯基) 本紙張尺度通用中國困家標準(CNS)甲4規格(210x297公垃) " -4 - (請先閲Τ*?背面之注意事項再填寫本頁) 裝- ,^τ· 線. Λ 6 13 6 經濟部屮央標準局貝工消費合作社印製 五、發明説明(3 ) 一丙基,4 一 (4 一氯苯基)一 丁基,2_ (4 —氣苯基 )一 1—甲基一乙基,3 — (4 —氣苯基)一 1—甲基一 丙基,4 (4 一氣苯基)一 1—甲基一 丁基,2 — (4 — 氣苯基)一 1—乙基一乙基,3— (4_氣苯基一 1_乙 基一丙基,4 一 (4 —氯苯基)一1 一乙基—丁基,2 — 苄氣基一乙基,2— (2—苯乙氣基)一乙基,2 — (3 —苯基—丙氧基)—乙基,2— (4_苯丁氧基)一乙基 ,2 — (5 —苯戊氣基)一乙基,2 — (6 —苯己氣基) 一乙基,2— (7—苯庚氣基一乙基,2— (4_甲氣苄 氧基)一乙基,2— 〔2_ (4 —甲氣苯基)一乙氧基〕 —乙基,2 —〔3 — (4 一甲氧苯基)_丙氣基〕一乙基 ,2 —〔4一 (4 一甲氧苯基)一丁氣基〕一乙基,2 — 〔5 — (4 一甲氣苯基)一戊氣基〕一乙基,2 —〔6 — (4_甲氣苯基)一己氣基〕一乙基,2 — 〔7 — (4 — 甲氧苯基)一庚氣基〕一乙基,3—苄氣基一丙基,3_ (2—苯乙氣基)一丙基,3_ (3—苯丙氣基)一丙基 ,3 — (4_苯丁氧基)一丙基,3 — (5 —苯戊氣基) 一丙基,3— (6—苯丁氧基)一丙基,3— (7—苯庚 氧基)一丙基,3— (4一甲氧苄氣基)一丙基,3 —〔 2 — (4_甲氣苯基)一乙氣基〕一丙基,3 — 〔3 — ( 4 一甲氣苯基)_丙氧基〕一丙基,3 —〔4 一 (4 一甲 氧苯基)一丁氧基〕一丙基,3 —〔5— (4 —甲氧苯基 )一戊氣基〕一丙基,3_〔6— (4 一甲氣苯基)一己 氧基〕一丙基,3 —〔7_ (4 —甲氣苯基)一庚氣基〕本紙張尺度逍用中國國家標準(CNS)甲4規格(210x297公龙) " (請先閱讀背面之注意事項再填寫本頁) 裝- Λ 6 13 6 五、發明説明(4 ) 一丙基,4一笮氣丁基,4一 (2—苯乙氣基)_丁基, 4 一 (3 —苯丙氣基)一丁基,4 一 (4_苯丁氧基)一 丁基,4一 (5—苯戊氣基)一丁基,4_ (6—苯己氣 基)一丁基,4 一 (7 —苯庚氣基)—丁基,4 一 (4一 甲氣笮氧基)一丁基,4一 〔2— (4 —甲氧苄基)一乙 氣基〕一丁基,4一〔3— (4_甲氧苯基)一丙氧基〕 一丁基,4一〔4二(4 一甲氣苯基)一丁氧基〕一丁基 ,4 一〔5— (4 —甲氣苯基)一戊氣基一丁基〕一丁基 ,4 一〔6 — (4 一甲氧苯基)一己氧基〕一丁基,4 一 〔7- (4一甲氧苯基)一庚氣基〕—丁基,5—苄氣基 經濟部中央標準局貝工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 庚基,5— (2—苯乙氧基)一戊基,5— (3—苯丙氧 基)一戊基,5 - (4一苯丁氧基)一戊基,5 — (5 — 苯戊氧基)一戊基,5— (6—苯己氣基)一戊基,5— (7—苯庚氧基)一戊基,5— (4一甲氧苄氧基)一戊 基,5—〔2— (4 一甲氣苯基)一乙氣基〕一戊基,5 一〔3 — (4 一甲氧苯基)一丙氧基〕一戊基,5 —〔4 一 (4 一甲氣苯基)一丁氧基〕一戊基,5 —〔5 — (4 一甲氧苯基)一戊氧基〕一戊基,5 —〔6 — (4 一甲氧 苯基)—己氧基一戊基,5 —〔7 — (4 一甲氣苯基)一 庚氣基一戊基,6—爷氧基一己基,6— (2—苯乙氧基 )一己基,6— (3 —苯丙氣基)一己基,6 — (4~苯 丁氧基)一己基,6_ (5—苯戊氣基)一己基,6—( 6_苯己氧基)一己基,6— (7—苯庚氧基)一己基, 6— (4_甲氣苄氧基)一己基,6_ 〔2— (4 一甲氧 本紙張尺度逍用中a Η家標準(CNS)甲4規格(210父297公釐) ~ — 經濟部中央標準局貝工消t合作社印製 Λ 6_13_6_五、發明説明$ ) 苯基)一乙氣基〕一己基,6 —〔3 — (4 一甲氧苯基) 一丙氣基〕一己基,6 〔4 一 (4 一甲氧苯基)一丁氣基 〕一己基,6 —〔5 — (4 —甲氣苯基)一戊氧基〕一己 基,6_ 〔6 — (4 一甲氣苯基)一己氣基〕一己基,6 一〔7— (4 一甲氣苯基)一庚氣基〕一己基,7 —苄氣 基一庚基,7— (2—苯乙氧基)一庚基,7— (3—苯 丙氧基)—庚基7— (4 一苯丁氧基)一庚基,7 — (5 一苯戊氣基)一庚基,7— (6—苯己氧基)一庚基,7 一 (7—苯庚氧基)一庚基,7— (4一甲氧笮氧基)_ 庚基,7— 〔2— (4_甲氣苯基)_乙氣基〕一庚基, 7— 〔3— (4一甲氣苯基)一丙氣基〕一庚基,7— 〔 4一 (4 一甲氣苯基)一丁氧基〕一庚基,7 —〔5 —( 4 —甲氧苯基)一戊氣基〕一庚基,7 — 〔6 — (4 —甲 氧苯基)一己氣基〕一庚氧基,7—〔7— (4 一甲氣苯 基)一庚氣基〕一庚基,2 — (4 -氯爷氣基)_乙基, 2 —〔2 — (4 —氣苯基)_乙氣基〕一乙基,2 —〔3 —(4 一氯苯基)一丙氧基〕一乙基,2—〔4_ (4一 氯苯基)一丁氧基〕一乙基,2— 〔5— (4_氣苯基) 一戊氣基〕一乙基,2 —〔6 — (4 一氯苯基)一己氣基 〕一乙基,2 —〔7 — (4一氯苯基)_庚氣基〕一乙基 ,3 — (4_氛苄氣基)_丙基,3 —〔2 — (4_氯苯 基)-乙氧基〕一丙基,3 -〔3 - (4-氣苯基)一丙 氧基〕一丙基,3—〔4 一 (4 一氯苯基)一丁氣基〕— 丙基,3-〔5— (4 一氛苯基)—戊氧基〕—丙基,3 本紙張尺度逍用中國困家標準(CNS)甲4規格(210X297公釐) ~ -7 - (請先閲讀背面之注意事項再填寫本頁) 裝. 訂 ,線. Λ 6 Β6 經濟部屮央標準局员工消t合作社印製 五、發明説明(i5 ) 一〔6 — (4一氯苯基)一己氧基〕一丙基,3—〔7 — (4 一氯苯基)一庚氣基〕一丙基,4 一 (4 一氯笮氧基 )一丁基,4—〔2 — (4 一氣苯基)一乙氣基〕一丁基 ,4 一〔3 - (4 一氯苯基)一丙氣基〕一丁基,4—〔 4 一 (4 一氣苯基)一丁氣基〕一丁基,4 一〔5_ (4 一氱苯基)一戊氧基〕一丁基,4一〔6- (4一氣苯基 )一己氧基〕一丁基,4一〔7— (4 一氣苯基)一庚氧 基〕一丁基,5 — (4_氣窄氣基)一戊基,5 —〔2 — (4 一氣苯基)一乙氧基〕一戊基,5 —〔3 — (4 —氯 苯基)一丙氧基〕一戊基,5-〔4 一 (4一氯苯基)一 丁氣基〕一戊基,5 —〔5 — (4 一氣苯基)一戊氧基〕 一戊基,5 —〔6 — (4 一氯苯基)一己氣基〕一戊基, 5 —〔7 — (4_氱苯基)一庚基〕一戊基,6 — (4 — 氯窄氧基)一己基,6 —〔2 — (4_氣苯基)一乙氣基 〕一己基,6—〔3— (4—氯苯基)一丙氧基〕一己基 ,6 —〔4一 (4 —氯苯基)一丁氣基〕一己基,6 —〔 5— (4 —氣苯基)一戊氣基〕一己基,6—〔6_ (4 一氣苯基)一己氧基〕一己基,6 —〔7_ (4 —氣苯基 )一庚氣基〕一己基,7_ (4 —氣笮氣基)一庚基,7 一〔2 — (4 一氯苯基)一乙氣基〕—庚基,7 —〔3 — (4_氛苯基)_丙氧基〕一庚基,7 —〔4 — (4 一氯 苯基)_丁氧基〕一庚基,7 -〔5 — (4—氯苯基)一 戊氧基〕一庚基,7—〔6— (4 一氯苯基)一己氣基〕 一庚基,7— 〔7— (4一氯苯基)一庚氧基〕一庚基, 本紙張尺度通用中國國家標準(CNS)甲4規格(210x297公逄) (請先閱讀背面之注意事項再填寫本頁) 裝< 訂 線· -8 - 經濟部中央標準局员工消費合作社印製 Λ 6 ___D_6 五、發明説明(7 ) 2 —(4 一羥苯基)一乙基,3 - (4 一羥苯基)一丙基 ,4 一(4 一經苯基)一丁基,2 -(4一翔苯基)一1 一甲基一乙基,3 — (4 一甲氣苯基)一1 一甲基一丙基 ,4 一 (4一經苯基)一1 一甲基一丁基,2 — (4 一經 苯基)一 1一乙基一乙基,3 — (4 一經苯基)一1—乙 基一丙基或4一 (4一翔苯基)一1一乙基一丁基。 通式(I)之較佳化合物為其中 R;示氫原子,甲氣羰基或乙氣羰基, m 示數字5, 6或7, η 示數字3,4或5, Ρ 示數宇1或2 , 示氫原子或羥基或甲氣基 R 4示氫原子,且 R 5不甲基, 其對映體及酸加成鹽。 依本發明,以上通式I之新穎化物可藉以下方法製得: 通式(I )之醛類 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度逍用中國Η家標準(CNS)甲4規格(210X297公¢) -9 - 五、發明説明β ) 0
CHO Λ 6 Β6
II (其中 R2如前所定義)或其水合物,在通式(I)之胺類 存在下還原 Η , Η· (HI) (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局貝工消費合作社印製 其中r2如前所定義。 還原作用是在以下條件下進行:在一溶劑如甲醇,乙 醇,丁醇,二乙醚,四氫呋喃或二噁烷,與錯合金屬氫化 物或與經催化性活化氫之存在下,於-20Ό到所使用之 溶劑沸點之g度間進行。 合宜地,使用錯合金屬氫化物如氫硼化鈉或氫化鋰鋁 之還原作用僳於一適合溶劑如甲醇,甲醇/水,,二乙醚 或四氫呋喃,在介於_20t:到所使用之溶劑的沸點間( 如在Ot:到5 Οΐ:間)進行。而使用經催化性活化氫之還
本紙張尺度逍用中國國家標準(CNS)甲4規格(210x297公;¢) Λ 6 IJ6 五、發明説明(9 ) 原作用係於催化劑如鉑,耙 ,R a n e y錄或R a n e y銘之存在 下,於0¾到1001c (較佳為室溫)及1到5atm之氫 壓下進行。 此反應可權宜地進行而無需分離形成於原位上之通式IV 之化合物
(請先閲讀背面之注意事項再填寫本頁) 裝- 經濟部中央標準局员工消費合作社印製 其中如前所定義,但此化合物當然可依上述 方法被分離及還原。 所獲得之通式I的新化合物,如有需要,可隨後被解 析成其對映體,此較佳傜藉將其非對映異構物之混合物與 一光學活性酸部分結晶而進行,該光學活性酸如D (-) 一酒石酸,L (+) —酒石酸,二苯甲醯基一D—酒p酸 ,二苯甲醯基一 L—酒石酸,(一)一樟腦一10 —磺酸 ,(+ ) —樟腦一 1 ◦一磺酸,L (一)一蘋果酸,D( 一)一扁桃酸,L (+) _扁桃酸,d-α—溴一樟腦一 π—磺酸或D (—) 一奎尼酸。然而,消旋體之分裂亦可 藉在光學活性或體物質如乙醯基纖維素上之管柱層析而進 行。 而且,消旋體之分裂亦可藉以下方式進行。解析非對 本紙張尺度逍用中國國家標準(CNS)甲4規格(210X297公釐) -11 - 附件2: 第 80107032號專利申請案中文說明書修正頁 民國8禅4 A./ . . ψ.— -.......-........
64. ] …心’:::‘.V: I Β7 五、發明説明(10 ) _____________.:ϊ二y 映異構化合物之混合物且隨後分裂不對稱佐藥,其中該化 合物係爲通式I之化合物與一不對稱化合物,諸如不對稱 醯基如N -保護胺基酸,碳酸之不對稱半酯,不對稱羧酸 或不對稱異腈酸酯。此類型之非對映異構化合物藉部分結 晶或在一惰性載體上之層析而得解析,且隨後之不對稱佐 藥之分裂可使利地藉水解或溶劑分解而進行。 而且,如需要,則通式I之新化合物可與無機酸或有 機酸一同轉變成爲其與一當量所論之酸的生理上可接受之 酸加成鹽。合適的酸包括,例如,氫氯酸,氫溴酸,硫酸 ,磷酸,乳酸,檸檬酸,酒石酸,蘋果酸或富馬酸。 作爲起始物質之通式π及m之化合物可藉一般本質上 已知的方法製備。因此,例如,通式π之化合物係藉以二 氧化硒氧化相關的乙醯苯酮而獲得(參見實例),而無需 分離所需之起始物質。 就如先前所述的,本發明之新化合物及其與無機酸或 有機酸的生理上可接受之鹽具珍貴之藥理性且可藉口服而 獲良好吸收;除了有止痛,消炎,消支氣管炎,子宮消痙 ’解脂效果及橫紋肌之抗痙攣效果之有,尙有-表情 和/或iSi _阻斷效果。且他們之獨特特徵在於口服之後 快速之效果顯出及常期活性。 藉由實例’以下A,B,C物質將V比較以調査其消 支氣管炎效果。 A=1 (4 —乙氧羰胺基_3 -氰基一 5 —氟—苯基 )—2 —〔6_ (4 —苯基—丁氧基)—己胺基〕—乙醇 本紙張尺度適用中國國家標隼(CNS ) A4規格(210X 297公釐) 訂 修 ---------!----^-装-- (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部中央梂準局負工消費合作社印製 12
—氫氯酸, B = l— (4 —胺基一 3 -氰基_5 -氣—苯基)— 2 —〔6 —(4 一苯丁氧基)_己胺基〕—乙醇—氫氯酸 y C=l— (4 —胺基一 3 —氰基一 5 -氟一苯基)— 2 —〔2 —(4 —甲氧苯基)一 1—甲基一乙胺基〕一乙 醇氫氯酸, V=1 -(4 —胺基—3,5-二氯—苯基)一 2 — 〔6— (4 —苯基—丁氧基)一己胺基〕—乙醇一氫氯酸 (參見EP-A-181709)。 消支氣管炎效果係依KONZETT及ROSSLER (Arch, exp. Path. Pharraak · 19 5,71 (1940)之對經 麻醉之天竺鼠測試安排而獲調查。E D 5。係從不同靜脈劑 量所得之由2 0 y g/kg之乙醯膽鹼所引致之支氣管痙攣 ,平均百分率之降低且藉[10£1?(5士31;151;15(:116阽61;11〇-den, 4th Edition, ρρ· 148—162 * Birkhauser, Base ( 1 9 6 4 )之線性回歸分析而計算。 (請先閱讀背面之注意事項再填寫本頁) 訂 i 經濟部中央標準局負工消費合作社印裝 本紙張尺度適用中國國家標準(CNS ) A4规格(2丨0 X 297公釐) _ 1 Q _ 13 五、發明説明ί2 ) 經濟部中央標準局貝工消費合作社印製 物質 在靜脈投服之後 Ε Ώ so u g/kg A 10.20 B 2.50 C 0.16 V > 4 0 0 (請先閱讀背面之注意事項再填寫本頁) 通式之新化合物極可接受且當化合物A到C以4 0 0 //g/kg之劑量靜脈投服至例如天竺鼠時,並無毒性副作 用被觀察到。 依本發明所製備之通式I化合物及其與無機或有機酸 之生理上可接受之鹽類因而適合tocolysis,藉周邊血管 擴張而降低血壓,蓮動身體脂肪或治療變應狀況如變應性 氣喘,或變應性發炎狀況,呼吸道,不同器官的痙孿或心 律失調,且為達此目的,任意與其它活物質結合時,他們 可被併入一&藥物製劑如一般的或包衣錠,溶液,噴霧劑 ,安瓿或坐藥中。人類中之單一劑量為1到5〇Wg,較 佳為2. 5到25wg,每天一或二次。 並且,通式I之新化合物及其酸加成鹽可用來治療極 肥胖之動物如狗,且因其身體脂肪之降低(脂肪分解)效 本紙張尺度边用中國國家標準(CNS)甲4規格(210X297公釐) ~~~ -14 - 經濟部屮央標準局员工消費合作社印製 Λ 6 _13_6_ 五、發明説明(13) 果,可用來降低存於耕種動物之不想要之脂肪,亦即改良 農業用動物如豬,失,綿羊和家禽之肉的品質。在動物中 ,上述化合物可藉口服或非口服途徑投服,如作為食品添 加劑或藉注射或藉植入小泵而投服。每日劑量在0. 01 及l〇〇/ig/kg體重之間,較佳在0. 01到l〇/2g / kg體重間。 並且,通式I之新化合物及其酸加成鹽可作動物之行 動加強劑以促進及加速成長,奶及毛的生産,且改良秣之 利用率,肉之品質且轉變肉比脂肪之比率而使肉增加。活 性物質用於農業的,養殖的,裝飾的及寵物動物上。 農業及養殖目的用之動物包括哺乳動物如失,豬,馬 ,綿羊,山羊,兔,野兔,鹿,供産毛皮用之動物如貂, 粟鼠,家禽如雞,鵝,鴨,火雞,魚,如鯉魚,蝉魚,鲑 魚,鳗魚,淡水魚,梭子魚和爬蟲類如蛇和蟠魚。 裝飾用及寵物動物包括哺乳類如狗和貓,鳥如鸚顧, 金絲雀,及魚如裝飾用及水族箱魚類如金魚。 活性物質用在整個動物之生長及行為上,而不管其性 別。活性物質較宜用在生長及行為加強期間。生長和行為 之加強期間隨著動物之種類持缠1個月到10年。 為要逹成所需之效果,投服至動物内之活性物質的數 量可因考慮活性物質之較佳性質而變化。劑量為每天 〇.〇1到50/ig/kg體重,更特別的是◦. 01到 2 5 w g/kg體重。活性物質之合宜數量並投服之正確期 間依動物類別,其年齡,性別,健康狀態及飼養及餵食動 本紙張尺度边用中國國家標準(CNS)甲4規格(210x297公釐) ^ -15 - (請先閱讀背面之注意事項再填寫本頁) 裝< 經濟部中央標準局員工消費合作社印製 Λ 6 136 五、發明説明α4) 物之方法而容易地由任何精於此技II之人來決定。 活性物質藉由一般方法來投服至動物内。投服方法持 別依動物類別,其行為及健康狀態而定。 活性物質可一次投服。然而,活性物質亦可在整個或 部分的生長期間,短暫或持缠地投服。在持缠投服之狀況 下,物質可在規或不規則的間隔内,每日一次或數次地給 予動物。 物質傺以合適之配方型或純物質型藉口服或非經腸途 徑投服。口服配方包括粉末,錠,顆粒,藥水,bo li及飼 料,飲水中之供投服用之飼料及配方之預混物。 口服製劑含有0. 01 ppb — 100%,較佳為 0. 0 1 ppb — 10%之活性物質濃度。 非經腸配方是溶液,乳液及懸浮液型之注射液以及植 入片〇 活性物質可單獨存在或與其它活性物質,礦物鹽,微 量元素,維生素,蛋白質,色素,脂肪或香料摻合而存在 〇 最終秣中之活性物質濃度一般約0. 〇lPPb _50 ppm,較佳 0 . 1 ppb — 1 0 ppm。 活性物質可以其本身形式或以預混物形式或飼料濃體 形式加入飼料中。 因此,依本發明之飼料除了含有活性物質12可能之 維生素/礦物質混合物外,更含有,例如,大麥,低级小 麥粉,蠶豆,撕碎之油菜萃取液及使豬肥胖之可食性脂肪 本紙^尺度逍用中S國家標準(CNS)甲4規格(210x297公釐) 二 ' -1D ~ (請先閲讀背面之注意事項再填寫本頁) 裝· 訂_ Λ 6 13 6 經濟部屮央標準局貝工消#合作社印製 五、發明説明(15) ;嫩雜用之玉米,大豆粉,肉粉,可食脂肪和大豆油;牛 用之撕碎之糖菜,玉米筋,以麥芽釀造之胚,大豆粉,小 麥及糖密;綿羊用之大麥,大豆粉,玉米及糖密。上述之 通式I化合物之一被加到此秣中作用活性物質,而濃度為 0 . 0 1 ppb 到 〇 . 5 0 %,較佳為 0 . 1 ppb 到 0. 05%。較佳是藉由活性物質預混物之方式來混合。 在預混物中之含量是例如5到10, OOOmg,較佳50 到1,000呢/10〇0克之玉米澱粉。 以下實例用來說明本發明。 奮例A R_ (4 —茱丁氬某)胺 溶於400毫升丙酮中之46. 6克(0. 15莫耳 )的6 — (4 —苯丁氣基)一己基溴及27. 6克( 0. 15莫耳)之酞醯胺鉀溶液被迴流70小時。在冷卻 之後,沈澱之溴化鉀藉抽吸過濾而除去且溶劑被真空蒸出 。因此所得之油狀殘餘物(其由粗製6_ (4 —苯基一丁 氧基)_N—己基酞醛胺組成)在300毫升之二氣甲烷 及300毫升之40%甲胺溶液中攪拌過夜。有機相被分 離且水相以二氣甲烷萃取兩次以上。經結合之有機相在硫 酸鈉上乾燥且真空蒸出。油狀殘餘物溶解於醚中,沈澱之 固體被濾出且濾液被蒸至乾。所餘之無色油狀物被蒸餾。 (請先閱讀背面之注意事項再填寫本頁) 裝< 本紙張尺度通用中家標準(CNS)甲4規格(210x297公釐) -17 — 經濟部中央標準局貝工消费合作社印製 五、發明説明(16) 富例B 2 - (4 —甲氮荣甚)一1 一甲某一7.胺 含32克(0. 21莫耳)之4’ 一甲氣苯乙酮和 165克(2. 1莫耳)之乙酸銨之甲醇(450毫升) 溶液與13. 5克(0· 2 1莫耳)之気基氫硼化鈉,此 氰基氫硼化鈉像在室溫下邊攪拌邊以批式加入。在另20 小時後,冰被加入且混合物以鹽酸(濃HC5 Η 2〇 = 1/1)酸化直到pH為2。酸性溶液以二氣甲烷萃取。 而後,水相與濃氨氣混合並冷卻直到發生清晰之鹼性反應 ,而後以二氯甲烷完全萃取。經結合之二氯甲烷萃取液在 硫酸鈉上乾燥且在真空下蒸發至乾。所得之粗製2— (4 —甲氣苯基)一 1 一甲基乙胺藉通過矽膠之管柱層析(洗 提液:二氯甲烷/甲醇=20/1)以除去任何副産物而 得純化。無色油狀物被獲得而可用來反應,無需進一步純 化。 窖例1 1一 (4 一乙氣羰基胺基—3 —氣基一5—氟苯基)一2 一〔6 — (4_苯基一丁氧基)一己胺基〕一乙醇一鹽酸 鹽 在601C並攪拌下,5克(0. 02莫耳)之4· 一 乙氧羰基胺基一3· —氰基一5, _氣一苯乙酮及1. 5 克之矽藻土被加到含2. 4克之二氣化硒之二噁烷(50 毫升)和水(3毫升)之溶液中。而後,混合物迴流4小 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度逍用中a Η家標準(CNS)甲4規格(210X297公;8:) -18 - Λ 6 Π 6 經濟部屮央標準局貝工消費合作社印製 五、發明説明(17) 時,而後過濾以除去固體。在冷卻之後,7克( 0. 025莫耳)之6 — (4 一苯基丁氣基)一己胺(像 溶解在一些二噁烷)被加到所得之4’ 一乙氣羰基胺基一 3' —氰基一5’ _氟苯基乙二醛溶液中。混合物在室溫 下靜置2小時之後,於攪拌並冷卻之條件下,以100毫 升之乙醇且3克之氫硼化鈉被加入。其在室溫下靜置過夜 。任何過多之氫硼化鈉以丙酮破壊,而後混合物在真空下 蒸乾。固髏殘餘物被分散在水和二氯甲烷中,且任何不溶 解的物質藉使用矽藻土之抽吸過濾而除去。濾餅以二氣甲 烷清洗3次以上。經結合之二氯甲烷溶液被乾燥且在真空 下蒸乾。固髏殘餘物藉通過矽膠之層析而純化,僳使用二 氯甲烷/甲醇=20/1和8/1作為濾液。在蒸發之後 所得殘餘物被溶在乙醇中。溶液以醚的鹽酸酸化至pH為 3。在加入酸後,發生結晶。 溶點:1 1 9 - 1 2 3它。 窨例2 1一 (4 一胺基一 3 —氣基一 5 —氣苯基)一 2 —〔6 — (4 一苯基一丁氧基)_己胺〕一乙醇一鹽酸鹽 從4. 一胺基一3, _氡基一5, 一氟苯乙酮及6— (4 一苯丁氣基)—己胺開始,依類似於實例1之方式製 備。 溶點:173-176C。 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度逍用中國Η家標準(CNS)甲4規格(210x297公龙) -19 - 五、發明説明α8) 1 一(4 乙氧 羰 基 胺 基 -3 2 -〔2 一 (4 一 甲 氧 苯 基) 醇一豳酸發 從4 1 -乙 氣 羰 基 胺 基一 乙_和2 ΦΜ — (4 一 甲 氧 苯基) 類似於實 例 1之方式 製 備 〇 熔點:1 2 3 - 1 2 5 V 0 EJ0L4- 1 - ( 4 一 胺基 — 3 — 気 基一 -(4 - 甲 氧一 苯 基 ) — 1 - 鹽 從4 • 一胺 基 — 3 1 -氮 —(4 一 甲 氣苯 基 ) — 1 一甲 例1之方式裂備 〇 熔點:1 5 6 — 1 5 8 t: 〇 一氰基一 5 —氟一苯基)一 一 1 一甲基一乙胺基〕一乙 3,—氣基一 5,_氟一苯 —1 一甲基一乙胺開始,依 5 —氣一苯基)一2 —〔2 甲基一乙胺〕一乙醇—鹽酸 基一 5’ 一氣_本乙嗣和2 基一乙胺開始,依類似於實 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度通用中國Β家標準(CNS)甲4規格(210x297公藿) -20 - 5 Λ 6 136 五、發明説明(19) 窨例5 含5 w g之1 - ( 4 —乙氧羰基胺基-3 —気基一 5 —氟 —苯基)一 2_〔6 - (4 —苯基—丁氣基)一己胺〕~ 乙醇一豳酴蘭____ 0 . 0 0 5 mg 8 2. 4 9 5 mg 3 3 . Ο Ο 0 mg 4 . Ο Ο Ο mg Q . 5 Q Q ηκ 1 2 Ο . Ο Ο Ο mg 1個錠含: 活性物質 乳糖 洋芋澱粉 聚乙烯吡咯酮 硬脂酸金ϋ 魁備方法 (請先閲讀背面之注意事項再填寫本頁) 裝- 訂·. · 線· 經濟部中央標準局员工消费合作社印製 活性物質及聚乙烯吡咯酮被溶解在乙醇中。乳糖和洋 芋澱粉之混合物活性物質/成粒溶液弄溼。使用1. 5毫 米之孔徑進行溼筛選。而後,在50¾下乾燥且使用 1 . 0毫米之孔徑進行乾鋪選。所得顆粒與硬脂酸鎂混合 且壓製成錠。 鍵重:1 2 0毫克 打印:7毫米,平坦 本紙張尺度通用中國S家標準(CNS)甲4規格(210x297公龙) -21 - Λ 6 13 6 五、發明説明以)) 窨例6 含1 ◦ /i g之1 一 (4 一乙氣幾基胺基一 3 —氰基一5 — 氟一苯基)一 2 — 〔2_ (4 —甲氣苯基)一 1 一甲基一 乙胺基〕一乙醇一鹽酸鹽之包衣錠 組成 1個鍵含: 活性物質 乳糖 洋芋澱粉 聚乙烯吡咯酮 硬脂酸鎂 0 . 0 1 0 mg 8 2. 4 9 0 mg 3 3 . Ο Ο 0 mg 4 . Ο Ο Ο mg _Ο . 5 Ο Ο mg 12 0. Ο Ο Ο mg (請先閱讀背面之注意事項再填寫本頁) 裝* 訂·- 經濟部中央標準局员工消費合作社印製 製備方法 包衣錠核心依實例5之類似方式製備。 核心重:1 2 0毫克 打印:7毫米,中凸狀。 核心依已知之方法,以實質上由糖和滑石組成之包衣 物來包衣。最後之包衣錠以蜂蟠來磨光。 包衣錠重:200. 0毫克。 線· 本紙張尺度逍用中因B家標準(CNS)甲4規格(210x297公龙) -22 - Λ 6 Β 6 五、發明説明(21) 奮例7 含5Wg之1— (4 一乙氧羰基胺基一 3 —氰基_5—氟 一苯基)一 2—〔6— (4 一苯基一丁氣基)一己胺基〕 _ 7.醇一鹽酸鹽之#圓_釁_ 1個錠含: 活性物質 0 . 0 〇 5 mg 乳耱 5 9 . 9 9 5 mg 玉米澱粉 6 0 . 〇 〇 〇 mg 12 0—. 〇 〇 〇 mg 剪備方法 活性物質與乳糖及玉米澱粉充份混合且填入於一合適 尺寸之長圓明膠膠囊中。 膠囊含量:120.◦毫克 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局貝工消費合作社印製 本紙張尺度逍用中國國家標準(CNS)甲4規格(210x297公龙) -23 - _136___ Λ 6 五、發明説明(22) 奮例8含2Wg之1— (4—胺基一 3 —氰基一 5_氟一苯基)一 2 —〔6 —(4 一苯丁基)_己胺基〕一乙醇一鹽酸鹽 /毎2裹并,安瓶__ 紐成 1値安瓿含: 活性物質 0 . 0 0 2 呢 檸樣酸 2 . 5 0 0 mg 磷酸氫鈉 7 . 5 0 0 mg 一般鹽 4 . 6 〇 0 mg 安瓿水添加至 2 . 0 0 0 mg (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局貝工消費合作社印製 製備方法 活性物質,缓衝物質和一般鹽溶在安瓿水中而後過濾 以除去任何病源。 包裝:在保護性氣體(N2 )條件下,裝入棕色2毫升之 安瓿。 消毒:在120 °C下20分鐘。 本紙張尺度边用中S困家樣準(CNS)甲4規格(210x297公婕) -24 - _136_ Λ 6 五、發明説明(23) 啻例9 含5wg之1一 (4一乙氧羰基胺基一3—氡基一5—氣 苯基)一2 — 〔2— (4 一甲氣苯基)一1 一甲基一乙胺 某Ί -7.醇一铺酸铺之坐藥_ 甜成 1個坐藥含: 活性物質 0.〇05mg 坐藥質體(如 Witepsol W4 5 ) 1699. 995ηκ 1700. OOOmg 製備方法 研細粉末狀之活性物質被拌入於冷卻至4 0*0之熔融 坐藥質體中,此係使用浸勻器。且在37Ό下,質體倒入 徹冷模中。 坐藥重:1 . 7克。 (請先閲讀背面之注意事項再填寫本頁) 裝· 經濟部中央標準局员工消費合作社印製 本紙張尺度通用中國國家標準(CNS)甲4規格(210x297公釐) -25 - Λ 6 _Β6_ 五、發明説明(24) 奮例1 0 含2 w g之1 一 (4 一乙氣幾基胺基一 3 —氰基一 5 —氣 一苯基)一2 —〔6— (4 —苯基一丁氣基)一己胺基〕 一乙醇一锸酴锞/毎5臺并夕糖務_ 紐成 1 0 0毫升糖漿含: (請先閲讀背面之注意事項再填寫本頁) 裝< -訂· .· 線- 經濟部中央標準局貝工消費合作社印製 製備方法 約60克之蒸餾水被加熱到801且苯甲酸,酒石酒, 活性物質,顔料及糖順序地溶於其中。在冷卻至室溫後, 香料被加入且混合物被添加到所需之體積。糖漿被過濾。 活性物質 0 . 0 4 mg 苯甲酸 0 . 1 0 mg 酒石酸 1 . 0 0 g 糖 5 0 . 〇 〇 g 桔香料 1 . 0 0 s 紅色食品色素 0 . 0 5 8 蒸餾水添加至 10 0 . 0 0 ml 本紙張尺度逍用中國國家樣準(CNS)甲4規格(210x297公釐) -26 - - Λ 6 _Β6_ 五、發明説明(25) 啻例1 1 含1/ig之1— (4一胺基一 3 —氰基一 5 —氣一苯基) 一 2 — 〔2 — (4 一甲氣苯基)一1 一甲基一乙胺基〕一 乙醇一鹽酸鹽/毎促動器之氣溶腰_ 組成 (請先閲讀背面之注意事項再填寫本頁) 裝- 經濟部中央標準局貝工消費合作社印製 審例1 2 含lwg之1一 (4一胺基一 3—氣基一 5 —氟一苯基) 一 2—〔6— (4_苯基丁氧基)一己胺基〕一乙醇一鹽 酸鹽/毎促動器之氣溶腰嚙割_ 組成 活性物質 0.00025mg 純乙醇 ’ 0 . 8 7 5 0 0 mg 氣霧劑氣體混合物 11/12/114 (23:54:23) 69. 12475ηκ 70. OOOOOmg 活性物質 0 . 〇 〇 0 2 5 mg 大豆卵磷脂 0 . 0 5 0 0 〇 mg 氣蓀劑氣體混合物 11/12/114 (23:54:23) 6 9 . 9 4 9 7 5 w, 7 0 . 〇 〇 〇 0 0 mg 本紙張尺度逍用中國國家標準(CNS)甲4規格(210x297公货) -27 - 經濟部中央標準局员工消費合作杜印製 Λ 6 _Β6_ 五、發明説明¢6 ) 啻例1 3 含59毫克之1一 (4一胺基一3—氮基—5—氟一苯基 )一 2—〔6— (4一苯基丁氧基)一己胺基〕一乙醇_ 翰酴镰/毎1 0 0裹升之趿人溶液_ 組成 活性物質 氣化鈉 苯醛氛 蒸餾水 製備方法 活性物質,一般鹽和苯醛氣被溶解在蒸餾水中,而後過 濾以除去病源。 奮例1 4 0 . 5 9 mg 9 0 0. 0 0 mg 2 5 . 0 0 mg a d 100. 00ml (請先閲讀背面之注意事項再塡寫本頁) 裝. 訂· 本紙張尺度逍用中國國家橾準(CNS)甲4規格(210X297公釐) -28 - 3似55 Λ 6 13 6 五、發明説明G7) 使豬HR胖之完今·飼料Ε 大麥 3 7 9 g / kg 低等小麥粉 2 0 0 8 / kg 樹薯粉 1 3 5 S / kg 蠶豆 1 〇 〇 S / kg 撕碎之油菜萃取液 1 0 0 g / kg 可食性脂肪 6 5 g /kg 豬之富賴胺酸礦物質飼料 2 〇 S /kg 活性物質預混物 1 g /kg 這些組成份以所示之量小心地 混合以 産 製 1公斤之 料。 1克之活性物質預混物含有, 例如 9 2 毫 克之依本 明之化合物及Ο. 998克之玉米澱粉。 曹例1 5 (請先閱讀背面之注意事項再填寫本頁) 裝· -訂· · 線- 經濟部中央標準局貝工消費合作社印製 本紙張尺度逍用中國國家樣準(CNS)甲4規格(210父297公釐) -29 - B6 五、發明説明(28) 橄雒;>增肥飼料I 玉米 6 3 4 g / kg 大豆粉 2 6 0 g / kg 肉粉 4 〇 S / kg 可食性脂肪 2 5 g / kg 大豆油 1 7 g /kg 磷酸 1 2 g /kg 碩酸鈣 6 g /kg 維生素/礦物質混合物 5 s /kg 活性物質預混物 1 g /kg
這些組成份以所示之量小心地混合以産製1公斤之飼 料。 1克之活性物質預混物含有,例如,1毫克之依本發 明之化合物及◦. 999克之玉米澱粉。 音例1 S (請先閱讀背面之注意事項再填寫本頁) 裝· 訂- 線. 經濟部中央標準局貝工消費合作社印製 本紙張尺度逍用中國國家標準(CNS)甲4規格(210X297公茇) -30 - Λ 6 13 6 五、發明説明<29 ) 牛飼料澹體 撒碎之糖菜 6 0 0 . 0 S / kg 玉米筋 1 0 0 . 0 g / kg 以麥芽釀造之胚 5 0 . 〇 g /kg 大豆粉 3 5 . 0 g / kg 小麥 1 1 9 . 0 s / kg 糖蜜 6 0 . 0 s / kg 可食性磷酸鹽 1 2 . 0 s / kg 碩酸鈣 2 . 5 g / kg 鹽 5 . 〇 g / kg 礦物質 1 0 . 0 s / kg 維生素預混物 5 . 5 g /kg 活性成份預混物 1 . 0 s /kg (請先閲讀背面之注意事項再場寫本頁) 裝- 1T< 經濟部中央標準局貝工消費合作社印製 這些成份以所示之量小心地混合以産製1公斤之 〇 1克之活性物質預混物含有,例如,2毫克之依本發 明之化合物及0. 998克之玉米澱粉。 審例1 7 本紙張尺度逯用中a國家標準(CNS)甲4規格(210X297公釐) ^ ~ 〇1 - Λ 6 13 6 五、發明説明00) 舖羊之增肥飼料 大麥 大豆粉 玉米 糖蜜 維生素/礦物質混合物 活性物質預混物 6 9 ◦ g / kg 1 ◦ ◦ g / kg 1 5 9 g / kg 3 0 g / kg 2 0 g / kg 1 g / kg 這些成份以所示之量小心地混合以産製1公斤之飼料 1克之活性物質預混物含有,例如,2毫克之依本發 明之化合物及◦. 998克之玉米澱粉。 (請先閱讀背面之注意事項再填寫本頁) 裝- 線- 經濟部中央標準局KX工消费合作社印製 本紙張尺度逍用中國國家標準(CNS)甲4規格(210X297公茇) -32 -
Claims (1)
- Λ8 B8 C8 D8 30^355 六、申請專利範圍 附件1(a):第80107032號專利申請案 中文申請專利範圍修正本 民國86年2月修正 1.通式(I)之苯乙醇胺 °ιΗ R. ⑴ CN (請先閲讀背面之注意事項再填寫本頁) 訂 其中, Ri示氫或甲氧羰基或乙氧羰基, R 2示下式之基團 經濟部中央梯準局員工消費合作社印製 :(CH2)m-〇-(CH2)n_R. 其中 m示數字5 ,6或7 η示數字3,4或5 Ρ示數字1或2,且 R 3示氫或甲氧基, 本紙張尺度適用中國困家梯準(CNS ) Α4規格(210Χ297公釐) 1 — I — ^55 Α8 Β8 C8 D8 Λ申請專利範圍 及其酸加成鹽。 2 ·如申請專利範圍第1項之通式(I )之化合物: 1- (4 —乙氧羰胺基—3—氰基一 5_氟一苯基)一 2 —〔6 — (4 —苯基丁氧基)—己胺基〕—乙醇, 工―(4 —胺基一3 —氛基一 5 —氟—苯基)—2 —〔6 —(4 一苯基丁氧基)_己胺基〕—乙醇, 以及其酸加成鹽。 3 .如申請專利範圍第1或2項之通式(I )之化合 物’其係該化合物之生理上可接受之酸加成鹽。 4.一種用於解除支氣管痙擊之藥學組成物,其含有 如申請專利範圍第1或2項之化合物或如申請專利範圍第 3項之生理上可接受之酸加成鹽,及任意之一或多種惰性 載體和/或稀釋劑。 (請先閲讀背面之注意事項再填寫本頁) 訂 Μ I. 經濟部中央橾準局負工消費合作社印製 本紙張尺度適用中國國家梯準(CNS ) Α4规格(210Χ297公釐) 302355 勺 附件二(a): 第80107032號專利申請案 中文補充實例 民國82年2月呈 審例18 1 — (4 —乙·® ^6 月安 — 3 — — 5 — 一 3j£ )— 2 — 〔4 — (2 — (4 —甲氧基一苯基)一乙氧基)—丁 基胺基〕—乙醇一鹽酸鹽 依實例1之類似方式,由4 ’一乙氧親基胺基一 3 ’ 一 氰基—5 ’ —氟苯乙酮及4 一〔 2 — ( 4 —甲氧基苯基) 一乙氧基〕丁基胺製備。 少容黑占:163 — 165°C〇 - 實例19 1 — (4 —胺基一3 —氯基一5 —氣一苯基)一2 —〔4 一(2 — (4—甲氧基一苯基)一乙氧基)丁基胺基〕一 乙醇一鹽酸鹽 依實例1之類似方式,由4 ’ 一胺基一3 ’ 一氡基一 5 一藏一苯乙銅和4 —〔2 — (4 —甲氯一苯基)一乙 氧基〕一 丁基胺製備。 太容 I占:158-160〇C
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4028398A DE4028398A1 (de) | 1990-09-07 | 1990-09-07 | Phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
Publications (1)
Publication Number | Publication Date |
---|---|
TW302355B true TW302355B (zh) | 1997-04-11 |
Family
ID=6413789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW080107032A TW302355B (zh) | 1990-09-07 | 1991-09-04 |
Country Status (16)
Country | Link |
---|---|
US (1) | US5393774A (zh) |
EP (1) | EP0500853B1 (zh) |
JP (1) | JP3164819B2 (zh) |
AT (1) | ATE146774T1 (zh) |
AU (1) | AU8426191A (zh) |
CA (1) | CA2073042C (zh) |
DE (2) | DE4028398A1 (zh) |
DK (1) | DK0500853T3 (zh) |
ES (1) | ES2097815T3 (zh) |
GR (1) | GR3022735T3 (zh) |
IE (1) | IE913136A1 (zh) |
NZ (1) | NZ239700A (zh) |
PT (1) | PT98884B (zh) |
TW (1) | TW302355B (zh) |
WO (1) | WO1992004316A1 (zh) |
ZA (1) | ZA917086B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996031466A1 (en) * | 1995-04-03 | 1996-10-10 | Laboratorios Almirall, S.A. | New ethanolamine derivatives |
JP3205315B2 (ja) * | 1999-04-28 | 2001-09-04 | リノール油脂株式会社 | ジオキサビシクロ〔3.3.0〕オクタン誘導体を有効成分とする体脂肪低減剤 |
ES2316599T3 (es) | 2001-09-14 | 2009-04-16 | Glaxo Group Limited | Derivados de fenetanolamina para el tratamiento de enfermedades respiratorias. |
CN1276911C (zh) * | 2001-09-30 | 2006-09-27 | 沈阳药科大学 | 具有β2-受体兴奋作用的新型苯乙醇胺类化合物及其制法 |
GB0217225D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
PT2346349E (pt) * | 2008-09-18 | 2015-02-04 | Elanco Animal Health Ireland | Utilização de azaperona para melhorar o desempenho do crescimento |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4119710A (en) * | 1972-12-18 | 1978-10-10 | Boehringer Ingelheim Gmbh | Bronchospasmolytic 1-(p-amino-phenyl)-2-amino-ethanols-(1) and salts |
NL8105170A (nl) * | 1980-12-10 | 1982-07-01 | Thomae Gmbh Dr K | Nieuwe fenylalkylaminen, werkwijze ter bereiding daarvan en de toepassing daarvan als geneesmiddelen. |
DE3104850A1 (de) * | 1981-02-11 | 1982-08-26 | Dr. Karl Thomae Gmbh, 7950 Biberach | "neuer futterzusatz zur verbesserung des wachstums" |
US4943591A (en) * | 1984-10-17 | 1990-07-24 | Glaxo Group Limited | Dichloroaniline derivatives |
GB8426191D0 (en) * | 1984-10-17 | 1984-11-21 | Glaxo Holdings Ltd | Chemical compounds |
DE3631009A1 (de) * | 1986-09-12 | 1988-03-24 | Bayer Ag | Arylethanolamine, verfahren zu ihrer herstellung und ihre verwendung zur leistungsfoerderung |
DE3718638A1 (de) * | 1987-06-04 | 1988-12-22 | Thomae Gmbh Dr K | Neue phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
-
1990
- 1990-09-07 DE DE4028398A patent/DE4028398A1/de not_active Withdrawn
-
1991
- 1991-09-03 DK DK91915303.1T patent/DK0500853T3/da active
- 1991-09-03 WO PCT/EP1991/001658 patent/WO1992004316A1/de active IP Right Grant
- 1991-09-03 ES ES91915303T patent/ES2097815T3/es not_active Expired - Lifetime
- 1991-09-03 JP JP51420891A patent/JP3164819B2/ja not_active Expired - Lifetime
- 1991-09-03 DE DE59108433T patent/DE59108433D1/de not_active Expired - Lifetime
- 1991-09-03 AU AU84261/91A patent/AU8426191A/en not_active Abandoned
- 1991-09-03 AT AT91915303T patent/ATE146774T1/de not_active IP Right Cessation
- 1991-09-03 EP EP91915303A patent/EP0500853B1/de not_active Expired - Lifetime
- 1991-09-03 CA CA002073042A patent/CA2073042C/en not_active Expired - Lifetime
- 1991-09-04 TW TW080107032A patent/TW302355B/zh not_active IP Right Cessation
- 1991-09-06 IE IE313691A patent/IE913136A1/en not_active IP Right Cessation
- 1991-09-06 NZ NZ239700A patent/NZ239700A/en not_active IP Right Cessation
- 1991-09-06 ZA ZA917086A patent/ZA917086B/xx unknown
- 1991-09-06 PT PT98884A patent/PT98884B/pt not_active IP Right Cessation
-
1994
- 1994-01-27 US US08/187,671 patent/US5393774A/en not_active Expired - Lifetime
-
1997
- 1997-03-03 GR GR970400427T patent/GR3022735T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
JPH05502455A (ja) | 1993-04-28 |
IE913136A1 (en) | 1992-03-11 |
ZA917086B (en) | 1993-03-08 |
JP3164819B2 (ja) | 2001-05-14 |
CA2073042A1 (en) | 1992-03-08 |
NZ239700A (en) | 1995-04-27 |
ES2097815T3 (es) | 1997-04-16 |
DK0500853T3 (da) | 1997-04-07 |
GR3022735T3 (en) | 1997-06-30 |
US5393774A (en) | 1995-02-28 |
WO1992004316A1 (de) | 1992-03-19 |
CA2073042C (en) | 2003-02-18 |
AU8426191A (en) | 1992-03-30 |
PT98884B (pt) | 1999-02-26 |
EP0500853B1 (de) | 1996-12-27 |
DE4028398A1 (de) | 1992-03-12 |
EP0500853A1 (de) | 1992-09-02 |
DE59108433D1 (de) | 1997-02-06 |
ATE146774T1 (de) | 1997-01-15 |
PT98884A (pt) | 1992-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5232946A (en) | Phenylethanolamines, their use as pharmaceuticals and as performance enhancers in animals | |
JPH0320225B2 (zh) | ||
GB2028799A (en) | Phenethanolamines | |
AU645313B2 (en) | Improved process for resolution of racemic cimaterol;(-)- cimaterol and derivatives thereof | |
TW302355B (zh) | ||
EP0029320B1 (en) | Secondary ethanol amines, their preparation and their use in pharmaceutical compositions | |
CN101602680B (zh) | 萘乙胺衍生物及其制备方法和在制备减肥药物方面的应用 | |
DE3146623A1 (de) | "neue phenylalkylamine, ihre herstellung und ihre verwendung als arzneimittel" | |
JP2005538146A (ja) | 新規なピペリジン―2,6−ジオンパモエート塩類及びストレス関連情動性疾患を治療・処置するためにこれらを使用する方法 | |
AU630710B2 (en) | (alpha-(tert.butyl aminomethyl)-3,4-dichlorobenzyl) thioacetamide, a procedure for its preparation and its uses | |
JPH02131468A (ja) | 動物成長促進活性と高度の安全性を持つ新規なピリジルアミノエタノール類 | |
PT89147B (pt) | Processo para a preparacao de novas feniletanolaminas e de composicoes farmaceuticas e de estimulantes de potencia ou de nutrientes para animais que as contem | |
NZ227196A (en) | Phenylethanolamine derivatives and their pharmaceutical and veterinary compositions | |
HU188686B (en) | Process for improving productivity of meat and utilization of food and/or ratio of meat-fat with phenyl-ethan derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Expiration of patent term of an invention patent |